Press releases
Teva and MODAG collaborate on licensing a drug candidate for neurodegenerative diseases (IZB Biotech News)
-- Drug candidate targets disease changes in multiple system atrophy and other neurological disorders like Parkinson --
PLANEGG/MARTINSRIED, Germany, November 2021 – MODAG GmbH, based in the Innovation and Start-up Center Biotechnology (IZB), and Teva Pharmaceutical Industries Ltd. in Tel Aviv announced in October 2021 a strategic collaboration for the exclusive worldwide licensing and development of MODAG’s lead compound anle138b and a related compound, sery433.
Teva and MODAG Announce Licensing Collaboration for Neurodegenerative Disease Drug Candidate (MODAG GmbH & Teva Pharmaceutical Industries Ltd.)
TEL AVIV & WENDELSHEIM, Germany, October 26, 2021 – Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) and MODAG GmbH today announced a strategic collaboration on the exclusive worldwide licensing and development of MODAG's lead compound anle138b and a related compound, sery433.
MODAG Initiates First-in-Patient Phase 1b Trial for Anle138b in Parkinson´s Disease (MODAG GmbH)
Wendelsheim, Germany – December 23, 2020 – MODAG, a German biotechnology company focused on the development of disease-modifying small molecule therapeutics for neurodegenerative diseases, today announced the clinical trial initiation of a first-in-patient Phase 1b study for anle138b in patients with mild to moderate Parkinson´s Disease (PD). Anle138b is a disease-modifying treatment option for synucleinopathies, such as Multiple System Atrophy (MSA) and PD.
MODAG Successfully Completes Phase 1 Study of their Lead Candidate Anle138b (MODAG GmbH)
-- Also receives Additional USD 1.4 Million from Michael J. Fox Foundation --
WENDELSHEIM, Germany, August 5, 2020 – MODAG, a German biotechnology company focused on the development of disease-modifying small molecule therapeutics for neurodegenerative diseases, today announced the successful completion of its first clinical trial of anle138b (NCT04208152) in healthy volunteers.
MODAG Initiates First-in-Human Phase 1 Clinical Trial for anle138b (MODAG GmbH)
--Worldwide patent for anle138b secured --
WENDELSHEIM, Germany, December 18, 2019 – MODAG, a German biotechnology company focused on the development of disease-modifying small molecule therapeutics for neurodegenerative diseases, today announced the clinical trial initiation of, and recruitment for, a first-in-human Phase 1 study of lead candidate, anle138b in healthy volunteers.
MODAG Appoints Dr. Johannes Levin as Chief Medical Officer (MODAG GmbH)
WENDELSHEIM, Germany, September 4, 2019 – MODAG today announced the appointment of Johannes Levin, M.D., as Chief Medical Officer (CMO).
MODAG Launches Out of Stealth Mode with Series A Financing of EUR 12 Million to Develop Treatments for Parkinsonian Disorders, Including Multiple System Atrophy (MODAG GmbH)
-- Dr. Torsten Matthias appointed CEO, scientific founder Prof. Dr. Armin Giese joins as CSO --
-- SERY technology in-licensed from Max-Planck Innovation GmbH to design next-generation candidate portfolio --
MODAG announced today the completion of a EUR 12 million Series A financing round, launching out of stealth mode to advance lead candidate anle138b into clinical development in Multiple System Atrophy (MSA).
New mouse model highlights promising potential drug for slowing Parkinson’s (Parkinson´s UK)
The results indicate that, when given early, the molecule Anle138b may restore dopamine levels and help slow or stop Parkinson’s in its tracks.
Researchers at the University of Cambridge, funded by Parkinson's UK, have developed a new animal model and shown that anle138b may slow down the progression of Parkinson's by targeting toxic alpha synuclein-clumps.
Putting the brakes on Parkinson’s
Experimental drug interferes with different mechanisms associated to Alzheimer’s disease
New drug against Alzheimer's and Parkinson's on the way (Max-Planck-Gesellschaft)